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ABSTRACT

Primitive or progenitor hematologic cancer cells have been
implicated in the early stages and development of leukemia
and malignant lymphoproliferative disorders, including
acute myelogenous leukemia (AML), chronic myelogenous
leukemia (CML) and chronic lymphoid leukemia (CLL).
Interleukin-3 receptor alpha chain (IL-3Ra or CD123) is
strongly expressed on progenitor hematologic cancer cells,
but is virtually undetectable on normal bone marrow cells.
The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic)
cells by selectively targeting cells expressing CD123. These
methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also
provided are compounds useful for selectively binding to
CD123 and impairing progenitor hematologic cancer cells.
These compounds may include cytotoxic moieties such as,
for example, radioisotopes or chemotherapeutics.
11 Claims, 8 Drawing Sheets
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METHODS TO IMPAIR HEMATOLOGIC
CANCER PROGENITOR CELLS AND
COMPOUNDS RELATED THERETO

This disease is characterized by premature arrest of myeloid
development and the subsequent accumulation of large
numbers of non-functional leukemic blasts. While leukemic
blast cells are often of clonal origin and display relatively
homogeneous features, it has been demonstrated that such
populations are organized in a hierarchical fashion, analogous to normal hematopoietic progenitors. Thus, there is a
phenotypically defined leukemic stem cell population that is
sufficient to propagate leukemic blasts both in vitro and in
vivo in xenogeneic mouse models of human AML (Bonnet
D, et al., Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic
cell. Nat. Med. 1997, 3: 730-737; Blair A, et al., Most acute
myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34
(+)/CD71(-)/HLA-DR-. Blood 1998, 92: 4325-35;
Cobaleda C, et al., A primitive hematopoietic cell is the
target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood 2000,
95: 1007-13; Blair A, et al. Lack of expression of Thy-1
(CD90) on acute myeloid leukemia cells with long-term
proliferative ability in vitro and in vivo. Blood 1997, 89:
3104-12). The concept of a leukemic stem cell (LSC)
becomes critically important in considering the etiology of
human disease. Clearly, in order to achieve durable remission, it will be necessary to specifically ablate the primitive
or progenitor LSC population. However, previous studies
(Terpstra W, et al., Fluorouracil selectively spares acute
myeloid leukemia cells with long-term growth abilities in
immunodeficient mice and in culture. Blood 1996, 88:
1944-50), as well as data from our group, suggest that LSC's
are biologically distinct from more mature leukemic blasts
and may not be responsive to conventional chemotherapeutic regimens. This observation is consistent with the clinical
profile frequently seen for AML, wherein a majority of
patients can achieve apparent complete remission, but in
most cases will relapse (Schiller G J., Treatment ofresistant
disease. Leukemia 1998, 12 Suppl 1: S20-4; Paietta E.,
Classical multidrug resistance in acute myeloid leukemia.
Med Oncol 1997, 14: 53-60). IfLSC's are more refractile to
chemotherapy than blasts, it is attractive to propose that
surviving stem cells are a major contributing factor to
leukemic relapse. Thus, strategies that specifically target
progenitor leukemia cells may provide more effective treatment for leukemia patients. In 1997, Bonnet and Dick
described the phenotype for LSC's as CD34+/CD38- (Bonnet D, et al., Human acute myeloid leukemia is organized as
a hierarchy that originates from a primitive hematopoietic
cell. Nat. Med. 1997, 3: 730-737). We report that the IL-3
receptor alpha chain (CD123) is highly expressed on leukemic but not normal CD34+/CD38- hematopoietic cells. In
view of this state of the art, there is a need in the art to
provide a diagnostic method for detecting leukemia at an
early stage, as well as more effective methods of treating this
disease.

CONTINUING DATA
The present application is a continuation of U.S. application Ser. No. 12/636,263, filed Dec. 11, 2009, now U.S.
Pat. No. 8,852,551, which is a continuation of U.S. application Ser. No. 10/830,089, filed Apr. 23, 2004, now U.S.
Pat. No. 7,651,678, which is a continuation of U.S. application Ser. No. 09/799, 100, filed Mar. 6, 2001, now U.S. Pat.
No. 6,733,743, which claims the benefit of priority to U.S.
Provisional Patent Application Nos. 60/187,123, filed Mar.
6, 2000, and 60/227,295, filed Aug. 24, 2000, the disclosures
of each of which are incorporated by reference herein in
their entirety.
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Field of the Invention
The present invention is related to methods of impairing
progenitor hematologic cancer cells or treating hematologic
cancer by targeting a cell surface marker specific for progenitor hematologic cancer cells. The present invention is
also related to a method for diagnosing hematologic cancer.
Background of the Invention
Stem cells are commonly found in a variety of mammalian tissue systems. While the criteria by which such cells are
defined vary depending upon the specific context, two
properties are generally regarded as central features of stem
cell populations: (1) stem cells must exhibit some capacity
for self-replication or self-renewal, and (2) stem cells must
be capable of differentiating into appropriate lineages (Patten CS: Stem Cells. London, Academic Press, 1997). Cells
of this nature have been described for a number of tissues
including hematopoietic, embryonic, neural, muscle and
hepatic systems (Lemischka I R. Clonal, in vivo behavior of
the totipotent hematopoietic stem cell. Semin Immunol
1991, 3: 349-55; Morrison S J, et al., The biology of
hematopoietic stem cells. Annu. Rev. Cell Dev. Biol. 1995,
11: 35-71; Robertson E J., Using embryonic stem cells to
introduce mutations into the mouse germ line. Biol Reprod
1991, 44: 238-45; Gage F H., Mammalian neural stem cells.
Science 2000, 287: 1433-8; and, Alison M, et al., Hepatic
stem cells. J Hepatol 1998, 29: 676-82). Thus, it is perhaps
not surprising that similar cells have recently been documented in the context of malignant populations (Bonnet D,
et al., Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic
cell. Nat. Med. 1997, 3: 730-737; Blair A, et al., Most acute
myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34
(+)/CD71(-)/HLA-DR-. Blood 1998, 92: 4325-35;
Cobaleda C, et al., A primitive hematopoietic cell is the
target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood 2000,
95: 1007-13). Indeed, a stem cell is in some respects the
ideal target for malignant transformation in that relatively
little biological change is required. Since stem cells already
possess the genetic programming necessary to be highly
proliferative and developmentally plastic, one can imagine
that relatively subtle perturbations might be sufficient to
induce disease.
One example of neoplasia arising from malignant stem
cells has recently been documented in the hematopoietic
system in the case of acute myelogenous leukemia (AML).
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The present invention relates to a method of using compounds that bind to the human CD123 molecule (CD123
ectopeptide), in the diagnosis and treatment of hematologic
cancers (e.g., leukemias and malignant lymphoproliferative
disorders). The CD123 specific compounds and mimetics
have particular utility as pharmaceuticals and reagents for
the therapy of hematologic cancer or malignant disease
states and for the diagnosis of hematologic cancer disease
states. In one embodiment, the present invention provides a

US 10,508,150 B2
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method of impairing a hematologic cancer progenitor cell
comprising contacting the cell with a compound that selectively binds to CD123 in an amount effective to impair the
progenitor hematologic cancer cell. This contacting step
may occur in various environments, including in vitro and in
vivo in the body of an animal, including a human.
Throughout this application, reference will be made specifically to leukemia in describing certain embodiments of
the present invention. However, it is understood that the
present invention is not limited to diagnosis and treatment of
leukemia or malignant lymphoproliferative disorders alone,
but to any disease in which the cancerous cells selectively
express CD123, which includes the genus of hematologic
cancer.
In one embodiment, the present invention is directed to a
method of detecting the presence of CD 123 on, for example,
a leukemia progenitor cell. Thus, the invention is also
directed to a method of diagnosing leukemia. It is understood that by using a labeled ligand to bind to CD123, it is
possible to detect the presence of leukemia progenitor cells.
Thus, it is also possible to diagnose the likelihood of the
onset of leukemia in patients possessing such leukemic
progenitor cells expressing CD123. The CD123 binding
ligand may be an antibody to CD123, or it may be any of a
variety of molecules that specifically bind to CD123. Furthermore, the label can be chosen from any of a variety of
molecules, including, but not limited to, enzymatic compounds, or non-enzymatic compounds that serve as a
reporter of the presence of the ligand which has bound to the
CD 123 molecule. Examples of such labels include those that
are, for example, radioactive, fluorescent, chemiluminescent
or absorbent-based, or a combination of the foregoing. In
one embodiment, an assay is provided for detecting the
presence of progenitor leukemia cells in a sample by detecting the presence of CD123 in the sample, which may be
accomplished by introducing a compound that selectively
binds to CD123 and determining whether the compound
binds to a component of the sample.
In another series of embodiments, the present invention
also provides compounds or molecules which mimic (mimetics) the three-dimensional structure of part or all of the
compounds such as peptides, antibodies, carbohydrates,
lipids or nucleic acids that bind to CD123, and in the case
of antibodies, of the binding pockets of the antibodies, or of
the complementarity determining regions (CDR's).
The present invention also provides pharmaceutical
preparations comprising a pharmaceutically acceptable carrier; and any one or more of the CD123 specific compounds
and mimetics described above.
In another set of embodiments, the present invention
provides a method for the treatment ofleukemia, comprising
administering to a human subject or other animal in need of
such treatment a therapeutically effective amount of the
compounds or their mimetic pharmaceutical compositions
described above.
In still another set of embodiments, the present invention
provides a method of selectively purging leukemic stem
cells from bone marrow. These stems cells may give rise to
leukemia progenitor cells, or they may be the progenitor
cells, which may be impaired by the method of the invention
using various compounds or their mimetics and cytotoxic
agents that may be contacted to either a bone marrow sample
or injected into a bone marrow of an individual, thereby
destroying at least some of the leukemic stem cells in the
bone marrow.

accompanying drawings which are given by way of illustration only, and thus are not limiting of the present invention, and wherein:
FIGS. lA and 1B show CD123 expression on normal and
leukemic hematopoietic cells. Representative examples of
CD123 labeling in cells derived from normal bone marrow
(panel A) or primary AML peripheral blood (panel B) are
provided. The inset polygon in panel A (left dot plot)
indicates the percentage of total bone marrow that is positive
for CD123 expression (7%). The smaller rectangular gate
indicates the proportion of total marrow strongly positive for
CD123 (1%). The center dot plot in panel A shows bone
marrow that was enriched for CD34+ cells by selection on
an immunoaflinity colunm (see methods). The gates indicate
the total CD34+ population and the CD34+/CD38- population. The histograms indicate the CD123 labeling for the
two gated populations. Panel B shows the same analysis for
the primary AML specimen. Ml markers in the histograms
indicate expression levels that are higher than 99% of
isotype control samples. For each specimen, 50,000-100,000
events were analyzed.
FIG. 2 shows CD123 expression on five primitive AML
populations. Five primary AML specimens were labeled
with CD34, CD38, and CD123 and analyzed by flow cytometry. The figure shows CD123 labeling for the CD34+/
CD38- gated populations from each sample. The dark
sections indicate CD123 staining and the light sections
indicate parallel labeling with an isotype control antibody.
Ml markers in the histograms indicate expression levels that
are higher than 99% of isotype control samples. For each
specimen, 50,000-100,000 events were analyzed. 2A:
Sample 1; 2B; Sample 2; 2C: Sample 3; 2D: Sample 4; 2E:
Sample 5.
FIGS. 3A and 3B show engraftment of CD123+ AML
cells in NOD/SCID mice. Sorted CD34+/CD123+ primary
AML cells were transplanted into an irradiated NOD/SCID
mouse. Six weeks post-transplant, bone marrow cells were
isolated and analyzed for the presence of human (CD45+)
leukemic cells. Panel A shows the CD34 vs. CD45 profile of
an engrafted specimen using antibodies that are specific to
human cells. Panel B shows the CD34 vs. CD123 profile of
the CD45+ gated human cell population. For each sample,
50,000 events were analyzed.
FIG. 4 shows CD123 and CD131 immunoblot analysis of
primary AML specimens. Five primary AML samples were
derived from peripheral blood and sorted to isolate the
CD34+ population, thus insuring a virtually pure leukemic
sample. In addition, the leukemic cell line TF-1 (TF-1) and
normal marrow CD34+ cells (normal CD34+) were included
as controls. Lysates were made from each population, subject to denaturing PAGE and analyzed by immunoblot with
an anti-CD123 antibody (top panel) or an anti-CD131 antibody (bottom panel). The arrowhead at the left of each panel
indicates the position of the IL-3Ra (CD123) and IL-3R~
(CD131) chains, respectively.
FIGS. SA, SB and SC show phosphorylation of signal
transduction components in response to IL-3. Three primary
AML samples (Lanes 1-3) were derived from peripheral
blood and sorted to isolate the CD34+ population. Samples
were treated with ( +) or without (-) 20 ng/ml IL-3 for 15
minutes, then lysed and subjected to PAGE. Each gel was
then electro-blotted and membranes were probed with antibodies specific to either total or phosphorylated protein for
Akt (A), Stat5 (B), and Mek-l(C). The lane labeled C on
each blot is an antibody control and is derived from NIH 3 T3
cells treated +/-50 ng/ml PDGF (A and C), or TF-1 cells
treated +/-25 ng/ml GM-SCF (B).
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The present invention will become more fully understood
from the detailed description given herein below, and the
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FIGS. 6A, 6B and 6C show CD123 expression in primary
ALL. Flow cytometric analysis of CD123 expression on
three independent primary ALL (acute lymphoid leukemia)
specimens. CD123 labeling is shown by the filled (dark)
plots and controls are shown by open plots.
FIGS. 7A, 7B and 7C show CD123 expression in primary
CML. Flow cytometric analysis of CD123 expression on
three independent primary CML (chronic myelogenous leukemia) specimens. CD123 labeling is shown by the filled
(dark) plots and controls are shown by open plots.

a large accumulation of non-functional immature cells and
the concomitant loss of functional cells. Chronic leukemias
progress more slowly, with cancer cells developing to full
maturity. Furthermore, the white blood cells may be myelogenous or lymphoid. Thus, certain forms of leukemia may
be, by way of example, acute lymphatic (or lymphoblastic)
leukemia (ALL); acute myelogenic leukemia (AML);
chronic lymphocytic leukemia (CLL); or chronic myelogenic leukemia (CML); and myelodysplastic syndrome.
"Malignant lymphoproliferative disorders" may refer to a
lymphoma, such as multiple myeloma, non-Hodgkin's lymphoma, Burkitt's lymphoma, and follicular lymphoma
(small cell and large cell), among others. For purposes of
this invention, at least some of the hematologic cancer cells
are characterized by cells that express CD123. Also, for the
purposes of this application, whenever leukemia or malignant lymphoproliferative disorders are mentioned, the diagnostic and treatment method of the invention applies generally to hematologic cancer.
As used herein, the term "introducing" shall mean any
means of delivery, whether in vivo or in vitro, including
simple contact.
As used herein, the term "mimetic" means a compound or
molecule which mimics the three-dimensional structures of
a site on CD123 to which a compound may bind, or the
compound may be a molecule that mimics a molecule that
binds to CD123. In the case of an anti-CD123 antibody
binding site, or paratope, or active site, "mimetic" means a
compound that mimics the three-dimensional structure of
any combination of the antibody hypervariable loops or
complementarity determining regions (CDR's).
As used herein, the term "mimic" means the threedimensional placement of atoms of the mimetic such that
similar ionic forces, covalent forces, van der Waal's or other
forces, and similar charge complementarity, or electrostatic
complementarity, exist between the atoms of the mimetic
and the atoms of the binding site of the compound such as
a peptide or an antibody such that the mimetic has a similar
binding affinity for CD123 as the parent compound and/or
such that the mimetic has a similar effect on the function of
CD123 in vitro or in vivo.
In the case of anti-CD123 antibodies, within the antigenbinding portion of an antibody, as is well-known in the art,
there are complementarity determining regions (CDRs),
which directly interact with the epitope of the antigen, and
framework regions (FRs), which maintain the tertiary structure of the paratope. In both the heavy chain Fd fragment and
the light chain of IgG immunoglobulins, there are four
framework regions (FRI through FR4) separated respectively by three complementarity determining regions (CDRl
through CDR3). The CDRs, and in particular the CDR3
regions, and more particularly the heavy chain CDR3, are
largely responsible for antibody specificity.
As used herein, the term "normal" means any nonpathogenic or non-pathology-related cells or conditions.
As used herein, the terms "primitive" and "progenitor"
shall be interchangeable.
As used herein, with respect to polypeptides and antibodies, the term "substantially pure" means that the polypeptides are substantially free of other substances with which
they may be found in nature or in vivo systems to an extent
practical and appropriate for their intended use. In particular,
the polypeptides are sufficiently pure and are sufficiently free
from other biological constituents of their host cells so as to
be useful in, for example, generating antibodies, sequencing,
or producing pharmaceutical preparations. By techniques
well known in the art, substantially pure polypeptides may
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DETAILED DESCRIPTION OF THE
INVENTION
Definitions
As used herein, the term "antibody" means an immunoglobulin molecule, or a fragment of an immunoglobulin
molecule, having the ability to specifically bind to a particular antigen. Antibodies are well known to those of
ordinary skill in the science of immunology. As used herein,
the term "antibody" means not only intact antibody molecules but also fragments of antibody molecules retaining
antigen-binding ability. Such fragments are also well known
in the art and are regularly employed both in vitro and in
vivo. In particular, as used herein, the term "antibody"
means not only intact immunoglobulin molecules but also
the well-known active fragments F(ab') 2 , Fab, Fv, Fd, VH
and VL.
As used herein, the terms "bind" or "bind(s)" shall mean
any interaction, whether via direct or indirect means, which
affects the specified receptor or receptor subunit.
As used herein, the terms "binds selectively to" shall
mean that the compound, composition, formulation, etc.
does not significantly bind IL3R beta chain, but does bind
IL3R alpha chain.
As used herein, the terms "CD123", "IL3R subunit alpha"
and "IL3Ra" shall be used interchangeably to mean an
antigenic determinant that is detectable in leukemia precursor cells as described herein, but not detectable on normal
cells as described herein.
As used herein, the term "compound" shall mean any
purity of active ingredient, including formulations, compositions, naturally-occurring plants or animals, etc. The compound may include molecules that are naturally occurring,
such as proteins, nucleic acids, single stranded nucleic acids,
lipids, carbohydrates, and antibodies. However, synthetic
versions of these naturally occurring molecules may be
made, so long as they bind CD123. The compounds may
comprise more than one component. For example, a compound may be a monoclonal antibody attached to a toxin. Or,
it may be a lipid attached to a label. The compounds may
further comprise mimetics, and aptamers, but which all
retain their specificity to CD123.
As used herein, the term "impair" shall mean any decrease
in functionality or activity (including growth or proliferative
activity).
As used herein, the term "hematologic cancer" refers to a
cancer of the blood, and includes leukemia and malignant
lymphoproliferative disorders, among others. "Leukemia"
refers to a cancer of the blood, in which too many white
blood cells that are ineffective in fighting infection are made,
thus crowding out the other parts that make up the blood,
such as platelets and red blood cells. It is understood that
cases of leukemia are classified as acute or chronic. Cancer
cells in acute leukemias are blocked at an immature stage.
However, they continue to multiply. Consequently, there is
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be produced in light of the nucleic acid and amino acid
sequences disclosed herein. Because a substantially purified
polypeptide of the invention may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the polypeptide may comprise only a small percentage by weight of the preparation. The polypeptide is
nonetheless substantially pure in that it has been substantially separated from the substances with which it may be
associated in living systems.
As used herein with respect to compounds or mimetics,
the term "substantially pure" means that the compounds are
substantially free of other substances with which they may
be found, in nature, in in vivo systems, or as a result of
chemical or other synthesis, to an extent practical and
appropriate for their intended use. In particular, the compounds are sufficiently pure and are sufficiently free from
other biological constituents of their hosts cells, or chemical
or physical constituents of their synthesis so as to be useful
in, producing pharmaceutical preparations. By techniques
well known in the art (U.S. Pat. No. 5,648,379; Colman, P.
G. Protein Science 3: 1687-1696, 1994; Malby, et al.,
Structure 2: 733-746, 1994; McCoy et al., J. Molecular Biol.
268: 570-584, 1997), substantially pure compounds or
mimetics, may be designed. Because a substantially purified
compound of the invention may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the compound may comprise only a small percentage
by weight of the preparation. The compound is nonetheless
substantially pure in that it has been substantially separated
from the substances with which it may be associated in
living, chemical or other systems.
Mimetics that Bind to CD123
Compounds that target CD123 can be found. Phage
display libraries can be used to determine the DNA encoding
the polypeptide that binds to CD123. The principles of this
approach are disclosed in U.S. Pat. No. 5,837,500, which is
incorporated by reference herein in its entirety. Other nonpeptide molecules that may bind to CD123 include nucleic
acids, and liposomes. Carbohydrates may also be used to
target CD123. It is possible that the compound may not be
a naturally occurring biological molecule. Such chemicals
may be made by combinatorial libraries which are well
known in the art, with the assay goal being the binding of the
chemical compound to CD123. Liposomes may ensconce
certain toxins or other cell-impairing substances or cellimaging compounds may be used to target CD123. Numerous variations and combinations of compounds as targeting
agents are contemplated by the method of the invention, so
long as CD 123 is targeted, with the know ledge that leukemia
detection and leukemia treatment is kept in mind.
Mimetics of Anti-CD123 Antibodies
It is also possible to use the anti-idiotype technology to
isolate or screen for compounds or mimetics which mimic
an epitope. Thus, an anti-idiotypic monoclonal antibody
which is the image of the epitope bound by the first
monoclonal antibody, since it effectively acts as an antigen,
may be used to isolate mimetics from a combinatorial
chemical, or other libraries, of chemical or other compounds, such as peptide phage display libraries (Scott and
Smith, Science 249: 386-390, 1990; Scott and Craig, Curr.
Opin. Biotechnol. 5: 40-48, 1992; Bonnycastle et al., J. Mal.
Biol. 258: 747-762, 1996). Hence, peptides or constrained
peptides mimicking proteins or other compounds, including
those with nucleic acid, lipid, carbohydrate or other moieties, may be cloned (Harris et al., Proc. Natl. Acad. Sci.
(USA) 94: 2454-2459, 1997).

Purely synthetic molecules, which may not occur in
nature and are therefore more resistant to catabolism, excretion or degradation, may be designed by the three-dimensional placement of atoms, such that similar ionic forces,
covalent forces, van der Waal's or other forces, and similar
charge complementarity, or electrostatic complementarity,
exist between the atoms of the mimetic and the atoms of the
antigenic binding site or epitope. These mimetics may then
be screened for high affinity binding to CD123 and detect
and/or impair the CD123 bearing cell in vitro or in vivo, as
described in more detail below.
Diagnostic and Pharmaceutical Preparations
The invention also relates to a method for preparing
diagnostic or pharmaceutical compositions comprising the
CD123 binding compound and its mimetics. The pharmaceutical preparation includes a pharmaceutically acceptable
carrier. Such carriers, as used herein, mean non-toxic materials that do not interfere with the effectiveness of the
biological activity of the active ingredients. The term
"physiologically acceptable" refers to a non-toxic material
that is compatible with a biological system such as a cell,
cell culture, tissue, or organism. The characteristics of the
carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include
diluents, fillers, salts, buffers, stabilizers, solubilizers, and
other materials that are well known in the art.
The anti-CD123 antibodies and mimetics may be labeled
by a variety of means for use in diagnostic and/or pharmaceutical applications. There are many different labels and
methods of labeling known to those of ordinary skill in the
art. Examples of the types oflabels which can be used in the
present invention include enzymes, radioisotopes, fluorescent compounds, colloidal metals, chemiluminescent compounds, and bioluminescent compounds. Those of ordinary
skill in the art will know of other suitable labels for binding
to the CD 123 binding compound, such as monoclonal antibodies, or mimetics thereof, or will be able to ascertain such,
using routine experimentation. Furthermore, the binding of
these labels to the CD 123 specific compounds or their
mimetics can be done using standard techniques common to
those of ordinary skill in the art.
In the case of antibodies, another labeling technique
which may result in greater sensitivity consists of coupling
the antibodies or mimetics to low molecular weight haptens.
These haptens can then be specifically altered by means of
a second reaction. For example, it is common to use haptens
such as biotin, which reacts with avidin, or dinitrophenol,
pyridoxal, or fluorescein, which can react with specific
anti-hapten antibodies.
Diagnostic and Treatment Kits
The materials for use in the assay of the invention are
ideally suited for the preparation of a kit. Such a kit may
comprise a carrier means being compartmentalized to
receive in close confinement one or more container means
such as vials, tubes, and the like, each of the container means
comprising one of the separate elements to be used in the
method. For example, one of the container means may
comprise a compound that binds to CD123, such as a
monoclonal antibody, or a mimetic thereof, which is, or can
be, detectably labeled with a label that is suitable for
diagnostic purposes or if treatment is desired, a cytotoxic or
impairing agent. In the case of a diagnostic kit, the kit may
also have containers containing buffer(s) and/or a container
comprising a reporter-means, such as a biotin-binding protein, such as avidin or streptavidin, bound to a reporter
molecule, such as an enzymatic or fluorescent label. In
addition to the chemical material, of course a means of
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instructions for using the kit is included, preferably for either
diagnosing leukemia, or treating leukemia. The instruction
means may be written on the vial, tube and the like, or
written on a separate paper, or on the outside or inside of the
container. The instructions may also be in the form of a
multi-media format, such as CD, computer disk, video and
so on.
Preparation of Immunotoxins
While the preparation of immunotoxins is, in general,
well known in the art (see, e.g., U.S. Pat. No. 4,340,535, and
EP 44167, both incorporated herein by reference), the inventors are aware that certain advantages may be achieved
through the application of certain preferred technology, both
in the preparation of the immunotoxins and in their purification for subsequent clinical administration. For example,
while IgG based immunotoxins will typically exhibit better
binding capability and slower blood clearance than their Fab'
counterparts, Fab' fragment-based immunotoxins will generally exhibit better tissue penetrating capability as compared to IgG based immunotoxins.
Additionally, while numerous types of disulfide-bond
containing linkers are known which can successfully be
employed to conjugate the toxin moiety with the binding
agent, certain linkers will generally be preferred over other
linkers, based on differing pharmacologic characteristics and
capabilities. For example, linkers that contain a disulfide
bond that is sterically "hindered" are to be preferred, due to
their greater stability in vivo, thus preventing release of the
toxin moiety prior to binding at the site of action.
Cross-linking reagents are used to form molecular bridges
that tie together functional groups of two different proteins
(e.g., a toxin and a binding agent). To link two different
proteins in a step-wise manner, hetero bifunctional crosslinkers can be used which eliminate the unwanted homopolymer formation. An exemplary hetero bifunctional crosslinker contains two reactive groups: one reacting with
primary amine group (e.g., N-hydroxy succinimide) and the
other reacting with a thiol group (e.g., pyridyl disulfide,
maleimides, halogens, etc.). Through the primary amine
reactive group, the cross-linker may react with the lysine
residue(s) of one protein (e.g., the selected antibody or
fragment) and through the thiol reactive group, the crosslinker, already tied up to the first protein, reacts with the
cysteine residue (free sulfhydryl group) of the other protein
(e.g., dgA).
The spacer arm between these two reactive, groups of any
cross-linkers may have various lengths and chemical compositions. A longer spacer arm allows a better flexibility of
the conjugate components while some particular components in the bridge (e.g., benzene group) may lend extra
stability to the reactive group or an increased resistance of
the chemical link to the action of various aspects (e.g.,
disulfide bond resistant to reducing agents).
The most preferred cross-linking reagent is SMPT, which
is a bifunctional cross-linker containing a disulfide bond that
is "sterically hindered" by an adjacent benzene ring and
methyl groups. It is believed that stearic hindrance of the
disulfide bond serves a function of protecting the bond from
attack by thiolate anions such as glutathione which can be
present in tissues and blood, and thereby help in preventing
decoupling of the conjugate prior to its delivery to the site
of action by the binding agent. The SMPT cross-linking
reagent, as with many other known cross-linking reagents,
lends the ability to cross-link functional groups such as the
SH of cysteine or primary amines (e.g., the epsilon amino
group of lysine). Another possible type of cross-linker
includes the hetero-bifunctional photoreactive phenylazides

containing a cleavable disulfide bond such as sulfosuccinimidyl-2-(p-azido salicylamido) ethyl-1,3'-dithiopropionate.
The N-hydroxy-succinimidyl group reacts with primary
amino groups and the phenylazide (upon photolysis) reacts
non-selectively with any amino acid residue.
Although the "hindered" cross-linkers will generally be
preferred in the practice of the invention, non-hindered
linkers can be employed and advantages in accordance
herewith nevertheless realized. Other useful cross-linkers,
not considered to contain or generate a protected disulfide,
include SATA, SPDP and 2-iminothiolane. The use of such
cross-linkers is well understood in the art.
Once conjugated, it will be important to purify the conjugate so as to remove contaminants such as unconjugatedA
chain or binding agent. It is important to remove unconjugated A chain because of the possibility of increased toxicity.
Moreover, it is important to remove unconjugated binding
agent to avoid the possibility of competition for the antigen
between conjugated and unconjugated species. In any event,
a number of purification techniques are disclosed in the
Examples below which have been found to provide conjugates to a sufficient degree of purity to render them clinically
useful. In general, the most preferred technique will incorporate the use of Blue-Sepharose with a gel filtration or gel
permeation step. Blue-Sepharose is a colunm matrix composed of Cibacron Blue 3GA and agarose, which has been
found to be useful in the purification of immunoconjugates.
The use of Blue-Sepharose combines the properties of ion
exchange with A chain binding to provide good separation of
conjugated from unconjugated binding.
The Blue-Sepharose allows the elimination of the free
(non conjugated) binding agent (e.g., the antibody or fragment) from the conjugate preparation. To eliminate the free
(unconjugated) toxin (e.g., dgA) a molecular exclusion
chromatography step is preferred using either conventional
gel filtration procedure or high performance liquid chromatography.
After a sufficiently purified conjugate has been prepared,
one will desire to prepare it into a pharmaceutical composition that may be administered parenterally. This is done by
using for the last purification step a medium with a suitable
pharmaceutical composition.
Suitable pharmaceutical compositions in accordance with
the invention will generally comprise from about 10 to about
100 mg of the desired conjugate admixed with an acceptable
pharmaceutical diluent or excipient, such as a sterile aqueous solution, to give a final concentration of about 0.25 to
about 2.5 mg/ml with respect to the conjugate. Such formulations will typically include buffers such as phosphate
buffered saline (PBS), or additional additives such as pharmaceutical excipients, stabilizing agents such as BSA or
HSA, or salts such as sodium chloride. For parenteral
administration it is generally desirable to further render such
compositions pharmaceutically acceptable by insuring their
sterility, non-immunogenicity and non-pyrogenicity. Such
techniques are generally well known in the art as exemplified by Remington's Pharmaceutical Sciences, 16th Ed.
Mack Publishing Company, 1980, incorporated herein by
reference. It should be appreciated that endotoxin contamination should be kept minimally at a safe level, for example,
less than 0.5 ng/mg protein. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office
of Biological Standards.
A preferred parenteral formulation of the immunotoxins
in accordance with the present invention is 0.25 to 2.5 mg
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conjugate/ml in 0.15M NaCl aqueous solution at pH 7.5 to
9.0. The preparations may be stored frozen at -10° C. to
- 70° C. for at least 1 year.
It is contemplated that most therapeutic applications of
the present invention will involve the targeting of a toxin
moiety (cytotoxic agent) to the CD123 leukemia marker.
This is due to the much greater ability of most toxins to
deliver a cell killing effect as compared to other potential
agents.
However, there may be circumstances such as when the
target antigen does not internalize by a route consistent with
efficient intoxication by immunotoxins, where one will
desire to target chemotherapeutic agents such as cytokines,
antimetabolites, alkylating agents, hormones, and the like.
The advantages of these agents over their non-antibody
conjugated counterparts is the added selectivity afforded by
the antibody. One might mention by way of example agents
such as steroids, cytosine arabinoside, methotrexate, aminopterin, anthracyclines, mitomycin C, vinca alkaloids,
demecolcine, etopside, mithramycin, and the like. This list
is, of course, merely exemplary in that the technology for
attaching pharmaceutical agents to antibodies for specific
delivery to tissues is well established.
One preferred cytotoxic moiety for use in the present
invention is a radioisotope, which can be coupled to or
conjugated with, for example, an anti-CD123 antibody.
Preferred radioisotopes include a-emitters such as, for
example, 211 Astatine, 212 Bismuth and 213 Bismuth, as well as
~-emitters such as, for example, 131 Iodine, 90Yttrium, 177Lutetium, 153 Samarium and 109 Palladium. Particularly preferred radioisotopes are 211 Astatine and 131 Iodine.
It is proposed that particular benefits may also be
achieved through the application of the invention to cell
imaging. Imaging of leukemia cells is believed to provide a
major advantage when compared to available imaging techniques, in that the cells are readily accessible.
Moreover, the technology for attaching paramagnetic,
radioactive and even fluorogenic ions to antibodies is well
established. Many of these methods involve the use of a
metal chelate complex employing, for example, an organic
chelating agent such a DTPA attached to the antibody (see,
e.g., U.S. Pat. No. 4,472,509). In the context of the present
invention the selected ion is thus targeted to the cancerous
area by the antibody, allowing imaging to proceed by means
of the attached ion.
In a preferred embodiment, in the method of the invention, the antibodies may also be fused to a protein effector
molecule by recombinant means such as through the use of
recombinant DNA techniques to produce a nucleic acid
which encodes both the antibody and the effector molecule
and expressing the DNA sequence in a host cell such as E.
coli. The DNA encoding the chimeric protein may be cloned
in cDNA or in genomic form by any cloning procedure
known to those skilled in the art. See for example Sambrook
et al, Molecular Cloning: A Laboratory Manual, Cold Spring
Harbor Laboratory, (1989), which is herein incorporated by
reference.
Fusion or conjugation of antibodies to various labels
produces a highly specific detectable marker that may be
used to detect the presence or absence of cells or tissues
bearing the particular molecule to which the antibody is
detected. Alternatively, the antibodies may be chemically
conjugated or fused to an effector molecule that is another
specific binding moiety, e.g. a ligand such as those described
above. In this form the composition will act as a highly
specific bifunctional linker. This linker may act to bind and
enhance the interaction between cells or cellular components

to which the fusion protein binds. Thus, for example, where
the fusion protein is a growth factor joined to an antibody or
antibody fragment (e.g. an Fv fragment ofan antibody), the
antibody may specifically bind antigen positive cancer cells
while the growth factor binds receptors on the surface of
immune cells. The fusion protein may thus act to enhance
and direct an immune response toward target cancer cells.
In Vitro Detection and Diagnostics
The method of using the compounds that bind to CD123
and their mimetics are suited for in vitro use, for example,
in immunoassays in which they can be utilized in liquid
phase or bound to a solid phase carrier. In addition, the
monoclonal antibodies in these immunoassays can be detectably labeled in various ways. Examples of types of immunoassays which can utilize the monoclonal antibodies and
their mimetics are competitive and non-competitive immunoassays in either a direct or indirect format. Examples of
such immunoassays are the radioimmunoassay (RIA) and
the sandwich (immunometric) assay. Detection of antigens
using the monoclonal antibodies and their mimetics can be
done utilizing immunoassays which are run in either the
forward, reverse, or simultaneous modes, including immunohistochemical assays on physiological samples. Those of
skill in the art will know, or can readily discern, other
immunoassay formats without undue experimentation.
The compounds that bind CD123 and mimetics can be
bound to many different carriers and used to detect the
presence of CD123 bearing leukemia cells, including progenitor cells. Examples of well-known carriers include
glass, polystyrene, polypropylene, polyethylene, dextran,
nylon, amylase, natural and modified cellulose, polyacrylamide, agarose and magnetite. The nature of the carrier can
be either soluble or insoluble for purposes of the invention.
Those skilled in the art will know of other suitable carriers
for binding various compounds, or will be able to ascertain
such, using routine experimentation.
For purposes of the invention, CD123 may be detected by
the compounds and their mimetics when present in biological fluids and tissues. Any sample containing a detectable
amount of CD 123 ectopeptide can be used. A sample can be
a liquid such as urine, saliva, cerebrospinal fluid, blood,
serum or the like; a solid or semi-solid such as tissues, feces,
or the like; or, alternatively, a solid tissue such as those
commonly used in histological diagnosis.
In Vivo Detection of CD123
In using the CD123 binding compounds and mimetics for
the in vivo detection of CD123, the detectably labeled
compound or its mimetic is given in a dose which is
diagnostically effective. The term "diagnostically effective"
means that the amount of detectably labeled compound,
such as monoclonal antibody or mimetic is administered in
sufficient quantity to enable detection of the leukemia cells
for which the compounds or mimetics are specific.
The concentration of detectably labeled compound or
mimetic which is administered should be sufficient such that
the binding to CD123 or CD123-bearing leukemia cells, is
detectable compared to the background. Further, it is desirable that the detectably labeled compound or mimetic be
rapidly cleared from the circulatory system in order to give
the best target-to-background signal ratio.
As a rule, the dosage of detectably labeled compound or
mimetic for in vivo diagnosis will vary depending on such
factors as age, sex, and extent of disease of the individual.
The dosage of the compound can vary from about 0.01
mg/kg to about 500 mg/kg, preferably about 0.1 mg/kg to
about 200 mg/kg, most preferably about 0.1 mg/kg to about
10 mg/kg. Such dosages may vary, for example, depending
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on whether multiple injections are given, on the tissue being
assayed, and other factors known to those of skill in the art.
For in vivo diagnostic imaging, the type of detection
instrument available is a major factor in selecting an appropriate radioisotope. The radioisotope chosen must have a
type of decay which is detectable for the given type of
instrument. Still another important factor in selecting a
radioisotope for in vivo diagnosis is that the half-life of the
radioisotope be long enough such that it is still detectable at
the time of maximum uptake by the target, but short enough
such that deleterious radiation with respect to the host is
acceptable. Ideally, a radioisotope used for in vivo imaging
will lack a particle emission but produce a large number of
photons in the 140-250 keV range, which may be readily
detected by conventional gamma cameras.
For in vivo diagnosis, radioisotopes may be bound to the
compound either directly or indirectly by using an intermediate functional group. Intermediate functional groups
which often are used to bind radioisotopes which exist as
metallic ions are the bifunctional chelating agents such as
diethylenetriaminepentacetic acid (DTPA) and ethylenediaminetetra-acetic acid (EDTA) and similar molecules. Typical examples of metallic ions which can be bound to the
monoclonal antibodies and mimetics of the invention are
111 In, 97Ru, 67Ga, 6sGa, n As, s9zr, 99mTc, 123 1 and 201Tl.
In the diagnosis method of the invention, the compounds
and mimetics can also be labeled with a paramagnetic
isotope for purposes of in vivo diagnosis, as in magnetic
resonance imaging (MRI) or electron spin resonance (ESR).
In general, any conventional method for visualizing diagnostic imaging can be utilized. Usually gamma and positron
emitting radioisotopes are used for camera imaging and
paramagnetic isotopes for MRI. Elements which are particularly useful in such techniques include 157 Gd, 55 Mn,
l62Dy, s2cr and s6Fe.
In the cell monitoring method of the invention, the
compounds and mimetics can be used in vitro and in vivo to
monitor the course of leukemia disease therapy. Thus, for
example, by measuring the increase or decrease in the
biological molecules associated with such a diseases or
changes in the concentration of CD123 ectopeptide or
CD 123 bearing leukemia cells present in the body or in
various body fluids, it would be possible to determine
whether a particular therapeutic regimen aimed at ameliorating the above leukemia disease is effective.
Prophylaxis and Therapy of Leukemia
The CD123 specific compounds can also be used therapeutically for treatment of leukemia in both humans and
other animals. The term, "therapeutically" or "therapy" as
used herein in conjunction with the method of the invention
is directed to using CD 123 binding compounds, such as
anti-CD123 monoclonal antibodies and their mimetics,
which denotes both prophylactic as well as therapeutic
administration and both passive immunization with substantially purified polypeptide products, and mimetics, as well as
gene therapy by transfer of polynucleotide sequences encoding the product or part thereof. Thus, the compounds and
mimetics can be administered to high-risk subjects in order
to lessen the likelihood and/or severity of leukemia relapse,
or administered to subjects already evidencing active leukemia disease.
For certain applications, it is envisioned that pharmacologic agents will serve as useful agents for attachment to the
compounds, particularly cytotoxic or otherwise anticellular
agents having the ability to kill or suppress the growth or cell
division of leukemia cells. In general, the invention contemplates the use of any pharmacologic agent that can be

conjugated to a CD123 binding compound and delivered in
active form to the targeted cell. Exemplary anticellular
agents include chemotherapeutic agents, radioisotopes as
well as cytotoxins. In the case of chemotherapeutic agents,
the inventors propose that agents such as a hormone such as
a steroid; an antimetabolite such as cytosine arabinoside,
fluorouracil, methotrexate or aminopterin; an anthracycline;
mitomycin C; a vinca alkaloid; demecolcine; etoposide;
mithramycin; calicheamicin, CC-1065 and derivatives
thereof, or an alkylating agent such as chlorambucil or
melphalan, will be particularly preferred. Other embodiments may include agents such as a coagulant, a cytokine,
growth factor, bacterial endotoxin or the lipid A moiety of
bacterial endotoxin. In any event, it is proposed that agents
such as these may be successfully conjugated to antibodies
in a manner that will allow their targeting, internalization,
release or presentation to blood components at the site of the
targeted leukemia cells as required using known conjugation
technology.
In certain preferred embodiments, cytotoxic agents for
therapeutic application will include generally a plant-, fungus- or bacteria-derived toxin, such as an A chain toxins, a
ribosome inactivating protein, a-sarcin, aspergillin, restirictocin, a ribonuclease, diphtheria toxin or pseudomonas exotoxin, to mention just a few examples. The use of toxinantibody constructs is well known in the art of
immunotoxins, as is their attachment to antibodies. Of these,
a particularly preferred toxin for attachment to antibodies
will be a deglycosylated ricin A chain. Deglycosylated ricin
A chain is preferred because of its extreme potency, longer
half-life, and because it is economically feasible to manufacture a clinical grade and scale.
In other preferred embodiments, the cytotoxic agent may
be a radioisotope. Preferred radioisotopes include a-emitters
such as, for example, 211 Astatine, 212 Bismuth and 213 Bismuth, as well as ~-emitters such as, for example, 131 Iodine,
90 Yttrium, 177 Lutetium, 153 Samarium and 109Palladium.
As used herein, a "therapeutically effective amount" of a
compound is a dosage large enough to produce the desired
effect in which the symptoms of leukemia or the likelihood
of onset ofleukemia is decreased. A therapeutically effective
amount is not, however, a dosage so large as to cause
adverse side effects, such as hyperviscosity syndromes,
pulmonary edema, congestive heart failure, and the like.
Generally, a therapeutically effective amount may vary with
the subject's age, condition, and sex, as well as the extent of
the disease in the subject and can be determined by one of
skill in the art. The dosage may be adjusted by the individual
physician or veterinarian in the event of any complication.
A therapeutically effective amount may vary from about
0.01 mg/kg to about 500 mg/kg, preferably from about 0.1
mg/kg to about 200 mg/kg, most preferably from about 0.2
mg/kg to about 20 mg/kg, in one or more dose administrations daily, for one or several days.
In the method of the invention, the compounds and their
mimetics can be administered by injection or by gradual
infusion over time. The administration of the compounds
and their mimetics may be, for example, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or
transdermal.
Preparations for parenteral administration include sterile
aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene
glycol, polyethylene glycol, vegetable oils such as olive oil,
and injectable organic esters such as ethyl oleate. Aqueous
carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
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Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and
nutrient replenishers, electrolyte replenishers (such as those
based on Ringer's dextrose), and the like. Preservatives and
other additives may also be present such as, for example,
antimicrobials, anti-oxidants, chelating agents, and inert
gases and the like.
Depending on the specific clinical status of the disease,
administration can be made via any accepted systemic
delivery system, for example, via oral route or parenteral
route such as intravenous, intramuscular, subcutaneous or
percutaneous route, or vaginal, ocular or nasal route, in
solid, semi-solid or liquid dosage forms, such as for
example, tablets, suppositories, pills, capsules, powders,
solutions, suspensions, cream, gel, implant, patch, pessary,
aerosols, collyrium, emulsions or the like, preferably in unit
dosage forms suitable for easy administration of fixed dosages. The pharmaceutical compositions will include a conventional carrier or vehicle and a CD123 binding compound
and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, and so on.
If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH
buffering agents and the like, such as for example, sodium
acetate, sorbitan monolaurate, triethanolamine oleate, and so
on.
The compounds of this invention are generally administered as a pharmaceutical composition which comprises a
pharmaceutical vehicle in combination with a CD123 binding compound. The amount of the drug in a formulation can
vary within the full range employed by those skilled in the
art, e.g., from about 0.01 weight percent (wt %) to about
99.99 wt% of the drug based on the total formulation and
about 0.01 wt% to 99.99 wt% excipient.
The preferred mode of administration, for the conditions
mentioned above, is oral administration using a convenient
daily dosage regimen which can be adjusted according to the
degree of the complaint. For said oral administration, a
pharmaceutically acceptable, non-toxic composition is
formed by the incorporation of the selected CD 123 binding
compound in any of the currently used excipients, such as,
for example, pharmaceutical grades of mannitol, lactose,
starch, magnesium stearate, sodium saccharine, talc, cellulose, glucose, gelatin, sucrose, magnesium carbonate, and
the like. Such compositions take the form of solutions,
suspensions, tablets, pills, capsules, powders, sustained
release formulations and the like. Such compositions may
contain between about 0.01 wt % and 99.99 wt % of the
active compound according to this invention.
Preferably the compositions will have the form of a sugar
coated pill or tablet and thus they will contain, along with the
active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, and the like; a disintegrant such as starch or
derivatives thereof; a lubricant such as magnesium stearate
and the like; and a binder such as starch, polyvinylpyrrolidone, acacia gum, gelatin, cellulose and derivatives thereof,
and the like.
It is understood that by "pharmaceutical composition", it
is meant that the CD123 binding compound is formulated
into a substance that is to be administered purposefully
diagnosing or treating leukemia in the individual. And, by
"pharmaceutical composition", it excludes those compositions that are used to administer to individuals as test
compounds for a purpose other than as a diagnostic or
treatment agent for leukemia.

The invention is described in further detail hereinbelow.
Several recent studies have suggested the presence and
importance of stem cells in both the genesis and perpetuation of AML. Phenotypically, cells described as CD34+/
CD38- or CD34+/HLA-DR- appear to play a central role in
the development of leukemic populations (Bonnet D, et al.,
Human acute myeloid leukemia is organized as a hierarchy
that originates from a primitive hematopoietic cell. Nat.
Med. 1997, 3: 730-737; Blair A, et al., Most acute myeloid
leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34( +)/CD71
(-)/HLA-DR-. Blood 1998, 92: 4325-35). Furthermore,
there is evidence suggesting that such cells may be relatively
resistant to chemotherapeutic drugs, and consequently contribute to the phenomenon of relapse (Terpstra W, et al.,
Fluorouracil selectively spares acute myeloid leukemia cells
with long-term growth abilities in immunodeficient mice
and in culture. Blood 1996, 88: 1944-50). Thus, a better
understanding of LSC biology and the characterization of
unique LSC antigens are essential to the development of
better treatments for AML.
While the various AML subtypes display considerable
diversity with respect to developmental characteristics, phenotype, cytokine responsiveness, etc., there appears to be a
marked degree of functional conservation at the level of
more primitive leukemic cells. This feature has been demonstrated by the work of Bonnet et. al., in which a CD34+/
CD38- subpopulation was shown to be sufficient to establish leukemia in NOD/SCID mice (Bonnet D, et al., Human
acute myeloid leukemia is organized as a hierarchy that
originates from a primitive hematopoietic cell. Nat. Med.
1997, 3: 730-737). Similar studies by others have corroborated the existence of leukemic stem cells for both AML and
CML and confirmed their relatively homogeneous phenotype and functional capacity (Blair A, Hogge et al., Most
acute myeloid leukemia progenitor cells with long-term
proliferative ability in vitro and in vivo have the phenotype
CD34(+)/CD71(-)/HLA-DR-. Blood 1998, 92: 4325-35;
Holyoake T, et al., Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94: 2056-64). However, to date, no
study has identified an antigenic feature of myeloid LSC's
that may allow their identification or preferential targeting
for ablative therapy. In this report, we have identified an
additional commonality among CD34+/CD38- AML stem
cells, expression of CD123, which facilitates their discrimination from normal hematopoietic stem cells. While the
CD123 antigen was readily detected at high levels onAML
cells, the IL-3 receptor~ chain, CD131, was not detected.
Our experiments indicate that the transcription factor
IRF-1 (Interferon regulatory factor- I) is over-expressed (in
6 of 6 primary AML specimens examined). Previous studies
by Korpelainen et. al. have shown that treatment of endothelial cells with IFN-y results in up-regulation of CD123
(Korpelainen EI, et al., Interferon-gamma upregulates interleukin-3 (IL-3) receptor expression in human endothelial
cells and synergizes with IL-3 in stimulating major histocompatibility complex class II expression and cytokine
production. Blood 1995, 86: 176-82). Similarly, our own
studies have shown that treatment of primary AML cells
with IFN-y increases expression ofCD123 (data not shown).
Thus, aberrant expression of interferon regulatory molecules
might play a role in controlling CD123 expression in AML
cells.
Expression of the CD 123 antigen formally demonstrates
that LSC's are biologically distinct from their normal stem
cell counterparts. Because CD123 is not readily found on
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normal hematopoietic stem cells, it provides a unique
marker that can be used to identify malignant tissue. This
feature may be useful for research purposes, as well as in
minimal residual disease (MRD) studies. Further, the
CD123 epitope represents a target to which therapeutic
strategies may be directed. Previous clinical trials have used
monoclonal antibodies against both the CD33 and CD45
antigens as a means to deliver radioisotopes to AML cells in
vivo (Appelbaum F R., Antibody-targeted therapy for
myeloid leukemia. Semin Hematol 1999, 36: 2-8.). In addition, several other recent studies have shown exciting results
using monoclonal antibodies specific to antigens on malignant cells such as CD20, CD52, and Her-2 (Maloney D G.,
Advances in immunotherapy of hematologic malignancies.
Curr Opin Hematol 1998; 5: 237-43; Sikic B I., New
approaches in cancer treatment. Ami Oneal 1999, 10 Suppl
6: 149-53). Antibodies to CD123 may be useful in a similar
paradigm and will be capable of delivering a cytotoxic hit
that specifically targets the leukemic stem cell population.
We have shown that CD123 represents a unique antigenic
marker for the identification of primitive leukemic cells
from a broad range of human specimens across a broad
range ofleukemic diseases. Our studies show that CD123 is
generally expressed at high levels and may be indicative of
previously uncharacterized aspects of leukemia biology.
The present invention will be further illustrated in the
following, non-limiting Examples. The Examples are illustrative only and do not limit the claimed invention regarding
the materials, conditions, process parameters and the like
recited herein.

using CD45-PE (Pharmingen) specific to human cells. To
analyze cells transplanted into NOD/SCID mice, bone marrow was harvested at 6-8 weeks post-transplantation. Cells
were blocked with the anti-Fe receptor antibody 2.4G2 and
25% human serum, followed by double-labeling with
human-specific CD34-FITC and CD45-PE antibodies. Control samples consisted of marrow cells from non-transplanted mice. In some cases, cells were also labeled with
CD123-PE to ensure sustained expression of the CD123
antigen. For each specimen 50,000-100,000 events were
analyzed. Using this approach, human cells could reliably be
detected to a frequency as low as 0.1 %. Any analysis falling
below 0.1 % positive cells was considered negative.
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EXAMPLES
Example I .-Materials and Methods: Cell
Processing
Primary AML cells were obtained from the peripheral
blood or bone marrow of patients. Normal bone marrow was
obtained as waste material following pathological analysis,
surgical marrow harvest, or from the National Disease
Research Interchange (NDRI). Marrow cells were depleted
of erythrocytes by suspending in 150 mM NH4 Cl+10 mM
NaHCO 3 for 5 minutes, followed by two washes with
phosphate buffered saline (PBS). Blood cells were subjected
to Ficoll-Paque (Pharmacia) density gradient separation to
isolate the mononuclear white blood cell compartment.
Resulting leukocytes from marrow or blood were then used
for immunoaffinity selection, and/or flow cytometric analysis or sorting. For CD34+ cell selection, the Miltenyi immunoaffinity device (varioMACS) was used according to the
manufacturer's instructions. In some cases, leukocytes were
cryopreserved at a concentration of 5xl07 cells/ml in freezing medium consisting of Iscoves modified Dulbecco
medium (IMDM), 40% fetal bovine serum (FBS) and 10%
dimethy lsulfoxide (D MSO).
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Cell samples were lysed at a concentration of 2xl0 7
cells/ml in PBS containing: 1% NP-40, 0.5% deoxycholate,
0.1 % sodium dodecyl sulfate (SDS), 1 mM sodium vanadate
(Na 3 VO4 ), 30 µI aprotinin (Sigma), 1 mM phenylmethylsulfonyl fluoride (Sigma), 1 µg/ml pepstatin, and 1 µg/ml
leupeptin (Oncogene Research); incubated on ice for 30
minutes, and centrifuged at 15,000xg for 10 minutes to
remove debris. The resulting protein lysate was then aliquoted and stored at -80° C. For immunoblot analysis,
protein lysates were thawed and mixed with sample buffer
and reducing agent (Novex, San Diego, Calif., per manufacturer's instructions), and heated at 70° C. for 10 minutes.
Samples were then immediately analyzed by denaturing
PAGE (Novex, 4-12% Bis-Tris or 7% Tris-Acetate gels)
using the equivalent of 4xl0 5 cells per lane. Following
electrophoresis, samples were electro-transferred onto
Immobilon-P membrane (Millipore) and probed with the
indicated antibodies. To detect CD123 (IL-3R alpha chain),
antibodies S-12 (Santa Cruz Biotech) or 9F5 (Pharmingen)
were used. For the analysis ofMek andAkt, protein-specific
and phosphoprotein-specific rabbit polyclonal antibodies
from New England Biolabs were used. Anti-Stat5 polyclonal
(Transduction Labs) and anti-phospho-Stat5 (New England
Biolabs) were used to analyze the phosphorylation status of
Stat5. All primary antibodies were detected using alkaline
phosphatase-conjugated secondary antibodies (Santa Cruz
Biotechnology) and the ECF reagent (Pharmacia Biotech)
per manufacturer's instructions. Blots were visualized using
a Molecular Dynamics STORM 860 system and
Imagequant™ Software.
Example 4.-NOD/SCID Mouse Assays
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Example 2.-Flow Cytometry
Cytokine receptors were detected by labeling with the
following monoclonal antibodies: CD 114-biotin, CD 116FITC, CD123-PE, CD131-biotin (all from Pharmingen),
CDl 17-PE (Coulter), and CD135-PE (Caltag). Biotinylated
antibodies were visualized by subsequent labeling with
streptavidin-PE (SA-PE, Becton Dickinson). PrimitiveAML
subpopulations were identified using CD34-FITC or CD34PE in combination with CD38-APC (Becton Dickinson).
Primary AML cells were identified in NOD/SCID mice

Example 3.-Immunoblots

NOD/SCID mice (Jackson Laboratories, Bar Harbor,
Me.) were exposed to 225 rads ofy-irradiation from a 137 Cs
source. Cells to be assayed were resuspended in 0.25 mis
HBSS (Hanks balanced salt solution, Gibco) with 2% FBS
and injected IV into the tail vein. For the analysis of some
sorted populations, lxl0 6 irradiated (2500 Rads) mouse
bone marrow cells were co-injected as carrier. After 6-8
weeks, animals were sacrificed and bone marrow was analyzed for the presence of human cells using flow cytometry
(see above).

60

Example 5.-Results
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Analysis of cytokine receptors demonstrates strong
expression of CD123 on primitive leukemic but not normal
cells. Multiparameter flow cytometry was used to analyze
the expression of cytokine receptors previously implicated
in the growth of malignant hematopoietic cells. While
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several receptors displayed interesting patterns of antibody
labeling, the most striking feature observed was a remarkably high and well-conserved level ofCD123 (IL-3R alpha
chain) expression amongst primary AML specimens. FIG. 1
shows representative examples of CD 123 labeling in normal
and leukemic tissue. In FIG. lA total normal marrow, as well
as more primitive subsets, are shown with respect to CD123
expression. Total marrow generally has about 7% positive
cells for CD123, but only about 1% of the population
expresses the antigen at high levels (see inset FIG. lA). The
CD34+ population of normal marrow also has readily evident CD123 expression (12% in FIG. lA, right histogram),
as would be expected for a population known to contain
hematopoietic progenitors. The labeling profile shown is in
good agreement with previous studies by Sato et. al. that
have also examined IL-3Ra levels on human CD34+ cells
(Sato N, et al., Expression and factor-dependent modulation
of the interleukin-3 receptor subunits on human hematopoietic cells. Blood 1993, 82: 752-61.). However, the more
primitive CD34+/CD38- compartment shows no significant
expression ofCD123 (<1 %). In contrast, primary AML cells
(FIG. 18) displayed high levels of CD123. In both the
overall CD34+ population, as well as the more primitive
CD34+/CD38- compartment, greater than 99% of the cells
were positive for CD123. FIG. 2 shows five additional
examples of CD123 labeling on CD34+/CD38-AML cells,
further demonstrating the strong expression of this antigen
on leukemic populations. Table 1 summarizes the experiments performed to date on the AML cell type, and shows
CD 123 levels for primitive cells of AML subtypes Ml, M2,
and M4. Of the 18 primary AML specimens examined,
CD123 was strongly expressed on the primitive leukemia
cells in all but two instances. The two samples which had
lower CD123 levels (samples AML-11 and AML-14, Table
1) both displayed a uniform shift in CD123 expression, but
had an overall labeling intensity that was dimmer than most
samples assayed. In many cases (9 of 18), CD123 negative
cells were virtually undetectable (0% or less than 1% ).
Conversely, expression of CD123 was not detected on 3 of
5 normal samples of CD34+/CD38- cells and was barely
detectable in two additional specimens (<l % ). These flow
cytometric analyses were confirmed using two different
anti-CD123 monoclonal antibodies to insure that the results
were not an artifact caused by the use of a particular
antibody.
The high level of CD123 expression found on all AML
subtypes examined implies that IL-3Ra might play a central
role in creating or maintaining the leukemic state. To form
the high affinity receptor for IL-3, both the a and ~ chains
(CD123 and CD131 respectively) are necessary. Thus,
expression ofCD131 was also examined by flow cytometry
on the AML specimens. Interestingly, while some expression was seen in bulk AML populations, in 15 of 15
specimens CD131 was never detected in the CD34+ compartment (data not shown).
Further data demonstrating CD123 expression in primary
ALL and primary CML cells, as well as non-Hodgkin's
lymphoma, are discussed in Examples 8 and 10.

capacity of CD123+ cells, transplantation studies using the
NOD/SCID mouse model system were performed. Three
primary AML specimens (AML-2, 5, and 15 from Table 1)
were assayed by flow cytometrically sorting CD34+/
CD123+ cells and transplanting them into irradiated NOD/
SCID mice. In addition, the remaining cells in the population (CD34-/CD123+/-) were also sorted and transplanted
in parallel. The data in FIG. 3 are a representative example
of one specimen that showed strong engraftment of leukemic cells at six weeks post-engraftment. Panel A shows total
bone marrow cells labeled with antibodies specific to human
CD34 and CD45. The flow cytometric profile clearly indicates that a large population of human cells (CD45+) is
present in the marrow. In addition, the population is divided
between CD34+ and CD34- subsets, similar to the proportions ofCD34 labeling seen in the original leukemic specimen. Panel B shows the same marrow sample gated only on
the CD45+ cells. The data indicate that all of the cells that
have proliferated in vivo are CD123 positive. Table 2
summarizes the data for the three specimens tested. In all
cases, the CD123+ cells were capable of engrafting the
NOD/SCID animals. Moreover, in all but one instance, the
CD123- populations did not contribute to in vivo repopulation. Thus, as defined by the NOD/SCID model, we
conclude that CD123 is expressed on the LSC.
Finally, as an independent means of confirming the leukemic origin of CD123 positive cells, flow cytometry was
used to sort CD34+/CD123+ cells from two leukemic specimens. These samples were cultured for four days, synchronized and then harvested for cytogenetic analysis. Examination of spreads from each specimen showed that 20 out of
20 metaphases was positive for the leukemia-specific translocation.

Example 6.-In Vivo Engraftment Properties of
Human CD123+ Leukemia Cells in NOD/SCID
Mice
Given the strong CD123 expression observed on the vast
majority of cells that phenotypically encompass the LSC
population, it appeared likely that CD123 would be useful as
a marker of LSC's. Therefore, to establish the functional
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To further corroborate the data obtained by flow cytometry, immunoblot studies were performed to analyze IL-3R
signal transduction components. For these studies, each
AML sample was derived from a peripheral blood specimen
and was sorted to isolate the CD34+ population, thus insuring a virtually pure leukemic sample. First, expression of
both the IL-3Ra and ~ chains were examined. With respect
to CD123, the data shown in FIG. 4 (top panel) clearly
demonstrate expression in all leukemic samples assayed.
The CD34+ cells derived from normal marrow (lane 2,
CD34+) also show a weak signal. This is consistent with the
data in FIG. lA, which show that normal CD34+ cells often
contain a small subset of CD123+ cells. However, CD123
expression was not detected by flow cytometry in the more
primitive CD34+/CD38- subset of normal cells (FIG. lA
and Table 1). Due to their low frequency, it was not possible
to obtain sufficient CD34+/CD38- cells of either normal or
AML origin for direct analysis by immunoblot. Nonetheless,
detection of a clear signal in the overall CD34+ population
corroborates the strong signal seen by flow cytometry for
AML cells. Another point to note is that the molecular
weight of the CD123 band appears to vary slightly between
AML samples. We have performed RT-PCR fingerprint
analyses of the same specimens and seen no obvious aberrancies (data not shown). Thus, it appears that varying
degrees of post-translational modification are the most likely
explanation for this observation. Consistent with the results
obtained by flow cytometry, expression of CD131 was not
detected (FIG. 4, bottom panel).
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To begin exploring a potential functional role for CD123,
we examined the response of primary AML cells to IL-3.
Typically, stimulation ofhematopoietic cells with IL-3 leads
to several well-characterized intracellular signal transduction events (Hara T, et al., Function and signal transduction
mediated by the interleukin 3 receptor system in hematopoiesis. Stem Cells 1996, 14: 605-18). Prevalent among these
events are phosphorylation ofMek-1, Akt, and Stat-5 (Songyang Z, et al., Interleukin 3-dependent survival by the Akt
protein kinase. Proc NatlAcad Sci USA 1997, 94: 11345-50;
Yagisawa M, et al., Signal transduction pathways in normal
human monocytes stimulated by cytokines and mediators:
comparative study with normal human neutrophils or transformed cells and the putative roles in functionality and cell
biology. Exp Hematol 1999, 27: 1063-76; Sutor SL, et al.,
A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-Raf and A-Raf. J Biol Chem 1999,
274: 7002-10; de Groot RP, et al., Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF
receptor family. Cell Signal 1998, 10: 619-28). Consequently, immunoblot studies were performed on these proteins to assess the degree of phosphorylation, both in the
presence or the absence ofIL-3 stimulation. The data, shown
in FIG. 5, show no detectable phosphorylation of Akt and
Stat5 in the absence of IL-3, and only a moderate level of
phosphorylation for Mek-1. Furthermore, in response to
IL-3 stimulation, no appreciable increase in phosphorylation
is seen for any of the proteins assayed. These results suggest
that CD123 present on the surface of primary AML cells
does not contribute significantly to signal transduction via
conventional IL-3 mediated pathways.

Example 10.----CD123 Expression in Lymphoma
Cells

Example 8.----CD123 Expression in Primary ALL
and Primary CML Cells
Similar experimental protocol as described in Examples 1
through 4 were followed, and the expression ofCD123 was
assayed in primary ALL and primary CML cells by flow
cytometry. The results were consistent with the results
obtained with expression of CD123 in primary AML in
Example 5. FIGS. 6A, 6B, and 6C show reproducibly that
the primary ALL cells express CD123. Moreover, FIGS. 7A,
7B, and 7C show reproducibly that the primary CML cells
also express CD 123.
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TABLE 1
Expression of CD123 in Primitive Leukemic
and Normal Cells.

Specimen

25

% CD123+ cells in
CD34+/CD38- population

FAB

AML

30
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Example 9.-CD123 Targeted Complement-Kill
Assay
50

By using a complement-kill assay, "Current protocols in
Immunology" Edited by John Coligan, Ada Kruisbeek,
David Margulies, Ethan Shevach, and Warren Strober, John
Wiley and Sons publishing, 1992, which is incorporated by
reference herein in its entirety, this experiment demonstrates
that CD123+ cells are preferentially targeted. In this experiment, we compared a typical AML specimen (i.e. CD123+)
to a normal bone marrow sample. For each specimen there
is an untreated control, a sample treated with complement
alone, and a sample treated with anti-CD123+ complement.
As shown in Table 3, there is a substantial complementkilling effect on the AML specimen, but no effect on the
normal marrow. This is true for both the overall sample, as
well as the more primitive CD34+ cells. Accordingly, this
experiment demonstrates that there is a difference between
the effect on normal and leukemic cells with respect to the
specificity for CD123.

Immunohistochemical analysis of tissue sections showed
that "diffuse large B cell lymphoma" is strongly positive for
expression of CD123. This is the most common form of
non-Hodgkin's lymphoma. Thus, in a B-cell derived cancer,
expression ofCD123 is consistent with the observation that
CD123 was also observed on ALL cells (i.e. another type of
B cell cancer). This observation directly identifies B cell
lymphomas as a target for therapies and diagnostics using
CD123.
All of the cited references are incorporated by reference
herein in their entirety.
Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention
specifically described herein. Such equivalents are intended
to be encompassed in the scope of the following claims.

AML-1
AML-2
AML-3
AML-4
AML-5
AML-6
AML-7
AML-8
AML-9
AML-10
AML-11
AML-12
AML-13
AML-14
AML-15
AML-16
AML-17
AML-18
Normal Marrow

MDS/AML
Ml
Ml
M4
M2
M4
nd
M4
M4
M2
MDS/AML
nd
Ml
M4
M4
Ml
Ml
M4

BM-1
BM-2
SM-3
BM-4
BM-5

na
na
na
na
na

100%
100%
95.2%
98.1%
99.7%
99.5%
100%
99.7%
99.8%
100%
70.2%
92.5%
97.5%
51.1%
98.1%
95.3%
98.9%
100%

0
<1%

0
0
<1%

FAB =French.American, British classification system
MDS/AML = myelodysplastic syndrome progressing to AML
na = not applicable

TABLE 2
Engraftrnent of CD123+ Populations in NOD/SCID Mice.
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Exp. Specimen
AML-2

Population
Assayed (N)

Cells Inj./
mouse

CD34+/CD123+ (3)

4.9

X

)0e6

CD34-/CD123+/- (3)

7.5

X

)0e5

CD34+/CD123+ (4)

2.5

X

)0e6

60
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AML-5

% CD45 +
cells/recip.
42%
18%
67%
nd
0.2%
0.1%
15%
6%
1%
12%
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TABLE 2-continued

What is claimed is:
1. A method for reducing the number of CD123-bearing
leukemia cells in a human diagnosed with myelodysplastic
syndrome, said method comprising administering to the
human a therapeutically effective amount of an antibody that
binds CD123, such that said administration causes a reduction in the number of leukemia cells in the human.
2. The method of claim 1, wherein the therapeutically
effective amount is a dosage of about 0.01 mg/kg to about
500 mg/kg.
3. The method of claim 1, further comprising monitoring
the amount of leukemia cells present in the human to
determine that the number of leukemia cells is reduced.
4. The method of claim 1, further comprising monitoring
the amount of CD123-bearing leukemia cells present in the
human to determine that the number of CD123-bearing
leukemia cells is reduced.
5. The method of claim 1, wherein the therapeutically
effective amount of the antibody is administered to the
human daily or for one or several days.
6. The method of claim 1, wherein the antibody 1s a
monoclonal antibody, F(ab') 2 , Fab, or Fv.
7. The method of claim 6, wherein the antibody 1s a
monoclonal antibody.
8. The method of claim 1, further comprising administering to the human an additional therapeutic agent.
9. The method of claim 8, wherein the additional therapeutic agent is a chemotherapeutic agent.
10. The method of claim 9, wherein the chemotherapeutic
agent is a steroid cytosine arabinoside, fluorouracil, methotrexate, aminopterin, an anthracycline, mitomycin C, a vinca
alkaloid, demecolcine, etoposide, mithramycin, calicheamicin, CC-1065, chlorambucil, or melphalan.
11. The method of claim 1, wherein the antibody is
administered intravenously, intramuscularly, subcutaneously, percutaneously, orally, parenterally, vaginally, ocularly, nasally, transdermally, or intraperitoneally.

Engraftment of CD123+ Populations in NO D/S CID Mice.

Exp. Specimen

3

N
nd

AML-15

= number of mice
= not detectable

Population
Assayed (N)

Cells Inj./
mouse

% CD45 +
cells/recip.

CD34-/CD123+/- (3)

2.5 x 10e6

CD34+/CD123+ (5)

2.1

CD34-/CD123+/- (3)

2.4 x 10e6

nd
nd
nd
2.1%
0.2%
0.8%
1.1%
0.9%
nd
nd
nd

X

10e6
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TABLE 3
CD123 Specific Complement-Kill Assay
Viability
Total Cells

CD34+

25

unstained control
complement only
anti-CD123 +
complement
Primary normal BM

68.53%
67.76%
21.31%

73.29%
77.17%
33.25%

30

unstained control
complement only
anti-CD123 +
complement

80.20%
79.42%
80.46%

78.20%
80.33%
81.51%

35

Primary AML specimen

* * * * *

